James B. Tananbaum - 22 Dec 2021 Form 4 Insider Report for PARDES BIOSCIENCES, INC.

Role: Director, 10%+ Owner
Signature: /s/ Dennis Ryan, Attorney-in-Fact for James B. Tananbaum
Issuer symbol: N/A
Transactions as of: 22 Dec 2021
Net transactions value: +$3,250,000
Form type: 4
Filing time: 23 Dec 2021, 15:52:41 UTC
Previous filing: 06 Oct 2021
Next filing: 30 Dec 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PRDS	Common Stock	Purchase	$3,250,000	+325,000		$10.00	325,000	22 Dec 2021	See Footnote	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each of Foresite Capital Fund V, L.P. ("Capital Fund V L.P.") and Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V L.P.") purchased 162,500 shares of the Issuer's Class A Common Stock in a block trade at $10 per share on December 22, 2021. Foresite Capital Management V, LLC ("FCMVLLC") and Foresite Capital Opportunity Management V, LLC ("FCOMVLLC") are general partners, respectively, of Capital Fund V L.P. and Opportunity Fund V L.P. Each of FCMVLLC, FCOMVLLC and Dr. Tananbaum, in his capacity as managing member of each of FCMVLLC and FCOMVLLC, disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein. In connection with the closing of Pardes Biosciences, Inc.'s (formerly known as FS Development Corp. II) business combination, shares of the Issuer's Class A Common Stock were reclassified as common stock.

Content

Each of Foresite Capital Fund V, L.P. ("Capital Fund V L.P.") and Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V L.P.") purchased 162,500 shares of the Issuer's Class A Common Stock in a block trade at $10 per share on December 22, 2021. Foresite Capital Management V, LLC ("FCMVLLC") and Foresite Capital Opportunity Management V, LLC ("FCOMVLLC") are general partners, respectively, of Capital Fund V L.P. and Opportunity Fund V L.P. Each of FCMVLLC, FCOMVLLC and Dr. Tananbaum, in his capacity as managing member of each of FCMVLLC and FCOMVLLC, disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein. In connection with the closing of Pardes Biosciences, Inc.'s (formerly known as FS Development Corp. II) business combination, shares of the Issuer's Class A Common Stock were reclassified as common stock.